Role of intestinal glucagon-like peptide-1 in hypoglycemia response impairment in type 1 diabetes  

作　　者：Chun-Han Cheng Wen-Rui Hao Tzu-Hurng Cheng 

机构地区：[1]Department of Medical Education,Linkou Chang Gung Memorial Hospital,Taoyuan City 33305,Taiwan [2]Division of Cardiology,Department of Internal Medicine,Shuang Ho Hospital,Ministry of Health and Welfare,Taipei Medical University,New Taipei City 23561,Taiwan [3]Division of Cardiology,Department of Internal Medicine,School of Medicine,College of Medicine,Taipei Medical University,Taipei 11002,Taiwan [4]Department of Biochemistry,School of Medicine,College of Medicine,China Medical University,Taichung City 404328,Taiwan

出　　处：《World Journal of Diabetes》2024年第11期2237-2241,共5页世界糖尿病杂志（英文）

摘　　要：This study critically examines the novel findings presented by Jin et al,which explores the role of intestinal glucagon-like peptide-1(GLP-1)in impaired counterregulatory responses to hypoglycemia in mice with type 1 diabetes.The study identifies intestinal GLP-1 as a significant determinant in the physiological responses to hypoglycemia,offering new insights into its potential implications for diabetes management.The editorial synthesizes these findings,discusses their relevance in the context of current diabetes research,and outlines potential avenues for future investigation of intestinal GLP-1 as a therapeutic target.This analysis underscores the need for continued research into the complex mechanisms underlying impaired hypoglycemia responses and highlights the potential of targeting intestinal GLP-1 pathways in therapeutic strategies for type 1 diabetes.

关 键 词：Intestinal glucagon-like peptide-1 Type 1 diabetes HYPOGLYCEMIA Counterregulatory response Mouse model 

分 类 号：R587.1[医药卫生—内分泌]